Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT).

ABSTRACT:

Objective

To determine the effect of population level implementation of a test-and-treat approach to correction of suboptimal vitamin D status (25-hydroxyvitamin D (25(OH)D) <75 nmol/L) on risk of all cause acute respiratory tract infection and covid 19.

Design

Phase 3 open label randomised controlled trial.

Setting

United Kingdom.

Participants

6200 people aged ≥16 years who were not taking vitamin D supplements at baseline.

Interventions

Offer of a postal finger prick test of blood 25(OH)D concentration with provision of a six month supply of lower dose vitamin D (800 IU/day, n=1550) or higher dose vitamin D (3200 IU/day, n=1550) to those with blood 25(OH)D concentration <75 nmol/L, compared with no offer of testing or supplementation (n=3100). Follow-u

SUBMITTER: Jolliffe DA 

PROVIDER: S-EPMC9449358 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature